A novel cytokine-receptor survival axis in chronic myeloid leukaemia

慢性粒细胞白血病的新型细胞因子受体生存轴

• 批准号: nhmrc : 565204
• 负责人: Dr Mark Guthridge
• 金额: $ 28.32万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-cytokine-receptor-myeloid-leukaemia/96685
• 关键词: novel; cytokine; receptor; survival; axis

Cancer cells grow and survive in an unrestrained manner. Current therapies target cancer growth, however they permit the long-term survival of some cancer cells and increase the possibility of drug resistance and disease relapse. We have identified a new molecular switch that is constitutively activated (unregulated) in leukemia. Targeting specific components of this unregulated cell survival may provide new and improved approaches for the development of therapeutics in the treatment of leukemia

癌细胞以不受限制的方式生长和存活。目前的疗法针对癌症生长，但它们允许一些癌细胞的长期存活，并增加耐药性和疾病复发的可能性。我们已经确定了一个新的分子开关，在白血病中被组成性激活（不受调节）。靶向这种不受调节的细胞存活的特定组分可能为开发治疗白血病的疗法提供新的和改进的方法